

This Series paper provides a summary of what is known about the funding, cost, and cost-effectiveness of sexual and reproductive health and rights interventions, interrogates the likely impacts of increasing or reducing future sexual and reproductive health and rights funding, and provides recommendations for policy and regulatory changes from an economic perspective. Interventions that target HIV and sexually transmitted infections, contraceptive interventions, and abortion care are among the most cost-effective health interventions worldwide, but their funding is under severe duress.
General Medicine
|15th Jan, 2026
|The Lancet
General Medicine
|15th Jan, 2026
|The Lancet
General Medicine
|15th Jan, 2026
|The Lancet
General Medicine
|15th Jan, 2026
|The Lancet
General Medicine
|15th Jan, 2026
|The Lancet
General Medicine
|15th Jan, 2026
|The Lancet
General Medicine
|15th Jan, 2026
|The Lancet